Brainstorm Cell Therapeutics Inc. (BCLI) insider have most recently took part in a trading activity. On Aug 31, 2017 Arbel Irit, Director bought 2,500 shares having total worth of $10,650 at the price of $4.26 per share, following the transaction a total of 155,833 shares owned by Arbel Irit.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 1 times by insiders. an employee of the company was the buyer in 1 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Brainstorm Cell Therapeutics Inc. (BCLI) traded up 0.71% on Aug 30, 2017, hitting $4.26. 47,664 shares of the company’s stock traded hands. Brainstorm Cell Therapeutics Inc. has a 52 week low of $2.09 and a 52 week high of $4.94. The company’s market cap is $46 million.
Brainstorm Cell Therapeutics Inc. (BCLI) last announced its earnings results on Aug 14, 2017. The company reported -0.06 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.15 by $0.09. During the same quarter in the previous year, the company posted -0.05 earnings per share.
|earnings per share||-0.06||-0.10||-0.09||-0.05||-0.07||-0.14||-0.12||-0.12|
Brainstorm Cell Therapeutics, Inc. was incorporated in the State of Delaware. The Company is a developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company’s core technology, NurOwn, is based on the scientific achievements of Professor Eldad Melamed, former Head of Neurology, Rabin Medical Center, and Tel-Aviv University, and Professor Daniel Offen, Head of the Neuroscience Laboratory, Felsenstein Medical Research Center (FMRC) at the Tel-Aviv University. The Company’s technology entails exploiting the patient’s own bone marrow stem cells to generate glial-like cells that may provide an effective treatment for Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD), Multiple Sclerosis (MS) and Spinal Cord Injury. It intends to apply the patent-pending technology to the development of innovative autologous cell therapeutic products, NurOwn, for treatment of neurological diseases. The Company’s aim is to provide neural-supporting stem cell transplants that are expected to maintain, preserve and possibly restore the damaged neurons, protecting them from further degeneration. The Company’s efforts are directed at the development of the technology from the lab to the clinic with the main objectives: developing the cell differentiation process according to FDA guidelines; demonstrating safety and efficacy first in animals and then in patients; and setting up centralized facilities to provide NurOwn therapeutic products and services for transplantation in patients. The Company holds exclusive worldwide rights to commercialize the technology, through a licensing agreement with Ramot, the technology transfer company of Tel Aviv University, Israel.
Latest posts by William White (see all)
- Insider Trading Activity in: Second Sight Medical Products, Inc. $EYES - July 19, 2018
- Insider Trading Activity in: Internationa Flavors & Fragrances, Inc. $IFF - July 19, 2018
- Insider Trading Update: Opko Health, Inc. $OPK - July 19, 2018